Literature DB >> 8063762

Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth.

F Czubayko1, A T Riegel, A Wellstein.   

Abstract

The growth and metastasis of solid tumors rely on the activities of polypeptide growth factors. However, numerous growth factors are expressed in tumors, and it is difficult to decipher which are essential for tumor progression. We found the secreted growth factor pleiotrophin (PTN) expressed at high levels in a number of human tumor cell lines as well as in tumor samples. To assess the role of PTN in tumor growth, we inactivated the PTN gene with PTN-targeted hammerhead ribozyme constructs. Cotransfection of PTN and of the ribozymes inhibited PTN-induced colony formation of PTN-responsive cells whereas a point mutant, catalytically inactive ribozyme was ineffective. Colony formation induced by transfections with a closely related growth factor (midkine) was not affected by the ribozymes. In human melanoma cells that express high levels of PTN mRNA, stable transfection with PTN-targeted ribozymes quenched production of PTN, inhibited colony formation of the cells, and prevented their tumor growth in mice. This demonstrates that expression of a growth factor can be a rate-limiting step for malignant progression and suggests that ribozymes could be used therapeutically to target tumor growth factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063762

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Efficient and specific ribozyme-mediated reduction of bovine alpha-lactalbumin expression in double transgenic mice.

Authors:  P J L'Huillier; S Soulier; M G Stinnakre; L Lepourry; S R Davis; J C Mercier; J L Vilotte
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C.

Authors:  Harold Pariser; Gonzalo Herradon; Laura Ezquerra; Pablo Perez-Pinera; Thomas F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

3.  Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta.

Authors:  K Meng; A Rodriguez-Peña; T Dimitrov; W Chen; M Yamin; M Noda; T F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 4.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 5.  Inhibition of fibroblast growth factors.

Authors:  A Wellstein; F Czubayko
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 6.  Message therapy: gene therapy that targets mRNA sequence and stability.

Authors:  K F Kozarsky; L A Couture
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

7.  Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus.

Authors:  A M Schulte; S Lai; A Kurtz; F Czubayko; A T Riegel; A Wellstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

8.  Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin.

Authors:  F Czubayko; A M Schulte; G J Berchem; A Wellstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

9.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.

Authors:  Marius Grzelinski; Florian Steinberg; Tobias Martens; Frank Czubayko; Katrin Lamszus; Achim Aigner
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

10.  A Pleiotrophin C-terminus peptide induces anti-cancer effects through RPTPβ/ζ.

Authors:  Zoi Diamantopoulou; Oya Bermek; Apostolos Polykratis; Yamina Hamma-Kourbali; Jean Delbé; José Courty; Panagiotis Katsoris
Journal:  Mol Cancer       Date:  2010-08-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.